Colon & Rectal Surgery
Audio Summaries

Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

This study aimed to evaluate the safety, tolerability, and preliminary efficacy of AC01, an oral ghrelin receptor agonist, in patients with heart failure with reduced ejection fraction (HFrEF). The results indicated that AC01 was generally safe and well tolerated over 28 days, with no major adverse events reported, suggesting potential for further investigation in larger trials.

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis

The authors aimed to evaluate the efficacy and safety of a 6-month treatment regimen for pulmonary rifampicin-resistant tuberculosis compared to the standard 9-month treatment in South Africa. The study found that the 6-month regimen was noninferior in achieving successful treatment outcomes and had a similar safety profile to the standard regimen. This suggests that the shorter treatment duration may be a viable alternative for managing rifampicin-resistant tuberculosis.

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

The authors aimed to evaluate the long-term outcomes of anti-CD19 CAR T-cell therapy (tisagenlecleucel) in patients with relapsed or refractory B-cell non-Hodgkin lymphomas over a median follow-up of 10.1 years. They found that approximately 32% of patients with large B-cell lymphoma and 47% with follicular lymphoma achieved lymphoma-free survival, with a notable persistence of B-cell aplasia in long-term responders. The study highlights the potential for durable remissions in this patient population, despite some risks of non-relapse-related mortality and secondary cancers.

Prevention and Treatment of Peanut Allergy

This paper investigates the effectiveness of early peanut protein introduction and immunotherapy in preventing and treating peanut allergy. The authors find that introducing peanut protein early significantly reduces allergy prevalence, with optimal prevention strategies differing for low and high-risk infants. Additionally, they highlight that immunotherapy is more effective when started in younger children, emphasizing the critical need for early intervention.

Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial

The authors aimed to evaluate the efficacy and safety of tirofiban, a glycoprotein IIb/IIIa receptor antagonist, in improving functional independence in patients with acute ischaemic stroke following successful endovascular reperfusion. In a multicentre, double-blind, randomized controlled trial involving 1,380 patients, tirofiban was found to significantly increase the likelihood of functional independence at 90 days compared to placebo, although there was no significant difference in the rates of symptomatic intracranial hemorrhage or mortality between the two groups.

Non-invasive removal of the Smart tracheal occlusion device for fetal congenital diaphragmatic hernia: a single-arm, open-label, phase 1 study

This study aimed to evaluate the effectiveness and safety of a novel non-invasive tracheal occlusion device (Smart-TO) for treating congenital diaphragmatic hernia (CDH) in fetuses, which eliminates the need for a second intervention to restore airway patency. The results demonstrated a 100% deflation rate of the device using magnetic resonance imaging, with all infants having the balloon successfully expelled from their airways at birth, indicating a significant advancement in fetal surgery for CDH. Overall, the findings suggest that the Smart-TO device is effective and safe for use in this clinical context.

Combined bladder-kidney transplantation: first-in-human feasibility trial

The authors investigate the feasibility and safety of combined bladder-kidney transplantation as a novel treatment for patients with terminal bladder dysfunction and end-stage kidney disease. The first-in-human trial demonstrated successful surgical outcomes, with the patient maintaining good renal and bladder function, sensation, and continence beyond six months post-transplantation, suggesting this approach may be a viable option for select patients requiring immunosuppression.

The UCL-Lancet Commission on Migration and Health: review of the state of progress

The authors review the progress made since the UCL-Lancet Commission on Migration and Health's 2018 publication, highlighting the urgent need for improved health care access for refugees and migrants amid rising global migration trends and the impacts of the COVID-19 pandemic. They emphasize the importance of incorporating health considerations into migration policies, establishing monitoring systems, and addressing the health consequences of climate change. Ultimately, the authors call for strong leadership and accountability to enhance the health outcomes and rights of people on the move.

Cefazolin for Methicillin-Susceptible <em>Staphylococcus aureus</em> Bacteremia

The authors aimed to determine whether cefazolin is noninferior to antistaphylococcal penicillins (flucloxacillin or cloxacillin) in treating methicillin-susceptible *Staphylococcus aureus* bacteremia, particularly regarding 90-day mortality rates. The study found that cefazolin demonstrated noninferiority in mortality outcomes and was associated with a lower incidence of acute kidney injury compared to the penicillin group.

Management of Differentiated Thyroid Cancer

The authors aim to establish a comprehensive framework for the risk-adapted management of differentiated thyroid cancer, emphasizing the importance of dynamic risk stratification throughout the patient's clinical journey. They explore how clinicopathological staging and molecular risk characterization inform personalized management plans, particularly in the contexts of active surveillance for low-risk cases and treatment options for advanced disease. The paper illustrates therapeutic decision-making processes that balance risks, benefits, and patient preferences to enhance management strategies.